Femara

FDA approves lapatinib with letrozole for advanced breast cancer.

Monday, February 1st, 2010

MedPage Today (1/31, Fiore) reported, “The FDA has approved a combination of lapatinib (Tykerb) and letrozole (Femara) to treat hormone-positive and HER2-positive advanced breast cancer in postmenopausal women.” The approval was based on “a company-sponsored study that found that women with HER2-positive disease who were taking the combination had survival [...]

Tykerb® plus Femara® Improves Quality-adjusted Survival in Women with HER2+ Metastatic Breast Cancer

Tuesday, October 13th, 2009

Researchers affiliated with a large Phase III international randomized trial have reported that Tykerb® (lapatinib) and Femara® (letrozole) improves quality-adjusted survival (Q-TWIST) compared with Femara alone in women with metastatic HER2+ breast cancer. The details of this study were presented at the 2009 ASCO Breast Cancer Symposium in San Francisco, October 8-10.[1]
Tykerb, an oral tyrosine [...]